Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1519)	1/9/2006 3:31:00 PM
From: tuck	Respond to of 4474

[AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes] >>Mol Cancer Ther. 2005;4:1900-1911 AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes Justin M. Summy1, Jose G. Trevino1, Donald P. Lesslie1, Cheryl H. Baker1, William C. Shakespeare2, Yihan Wang2, Raji Sundaramoorthi2, Chester A. Metcalf, III2, Jeffrey A. Keats2, Tomi K. Sawyer2 and Gary E. Gallick1 1 Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, Texas and 2 ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts Requests for reprints: Gary E. Gallick, Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Box 179, Smith Research Building, 7777 Knight Road, Houston, TX 77054. Phone: 713-563-4919; Fax: 713-563-5489. E-mail: ggallick@mdanderson.org c-Src is frequently activated in human malignancies, including colon, breast, and pancreatic carcinomas. Several recent studies have shown that activation of Src family kinases leads to tumor progression and metastasis by increasing cellular migration and invasion, promoting cell growth and survival, and deregulating expression of proangiogenic molecules. Therefore, selective inhibitors of Src are being developed for cancer therapy. In this study, we characterize the biological effects of the novel ATP-based Src family kinase inhibitor, AP23846, in tumor cells with high Src activity. As a lead compound, AP23846 is a potent c-Src kinase inhibitor (IC50 0.5 nmol/L in vitro, 10-fold more potent than PP2, the most widely used commercially available Src family kinase inhibitor). At concentrations of 1 µmol/L, AP23846 led to complete Src inhibition for 48 hours in cells. No cytotoxicity was observed under these conditions, although proliferation rates were slower. Therefore, this was an excellent inhibitor to examine Src-regulated signaling pathways in tumor cells. AP23846 reduced cellular migration, vascular endothelial growth factor, and interleukin-8 in a dose-dependent fashion in pancreatic adenocarcinoma cells grown in vitro. Correspondingly, cell culture supernatants from L3.6pl pancreatic adenocarcinoma cells pretreated with AP23846 failed to promote migration of hepatic endothelial cells in vitro and failed to support angiogenesis into gel foams implanted s.c. in mice in vivo. These results suggest that Src inhibitors affect biological properties of tumor progression and may be useful as cancer therapeutic agents in more advanced disease.<< Cheers, Tuck